The first proof-of-concept study targeting interactions of 14-3-3 proteins in vivo was reported by Fu et al., who generated difopein, a dimeric form of R18, which disrupted 14-3-3 PPIs, increased the ability of cisplatin to kill cells and triggered tumor cell apoptosis (Masters and Fu, 2001; Cao et al., 2010). The gene discussed is YWHAQ; the disease is neoplasm.